The growth finance checklist: 25 things to have in place for healthcare and life sciences in Southern Europe
A single-page checklist to audit whether your growth finance setup is production-grade or a science project. Written for commercial leaders at healthtech, medtech, and life-sciences companies in Southern Europe.
This edition of the Growth Broker playbook is written for commercial leaders at healthtech, medtech, and life-sciences companies operating in Southern Europe. In this market, Southern European buyers reward relationship depth over transactional outreach, so the way you install growth finance has to be shaped to that reality from day one.
Use this as a pre-flight before you commit spend to growth finance. Each item takes minutes to check and hours to fix later.
List, trigger, message. If any of the three is generic, stop and fix the generic one before you touch the other two. Generic list plus sharp message beats sharp list plus generic message, but only for a week.
Owner, cadence, metric. One named human owns the model. The cadence is written down. CAC payback and gross margin is the number in every review.
Inside healthcare and life sciences, the binding constraint is almost always regulated-sale cycle length, not intent, and in Southern Europe it is compounded by the fact that relationship depth, not activity volume is what actually gates growth. Growth finance is only useful here when it is pointed at both constraints at once.
Data, tooling, workflow. Data flows to one place. Tooling is minimal. Workflow survives the owner going on holiday.
Quality gate, kill criteria, learning loop. Nothing ships without a human eyeballing it. Anything below the bar dies inside a week. What you learn feeds Monday.
Ethics, brand, deliverability. You will not do anything on this list you would not want on the front page. Brand is protected. Sending infrastructure is separated from the primary domain.
Governance, budget, escalation path. Someone above the owner cares. Budget is finite and defended. Bad news travels up in hours, not weeks.
If more than three of these are missing, growth finance is not going to produce a durable CAC payback and gross margin. Fix them in order and re-run the checklist in a month.
Concretely for healthcare and life sciences in Southern Europe: the healthcare teams that install this get past procurement instead of dying in it, and a single trusted Southern European relationship compounds into a regional beachhead. That is the reason it is worth installing growth finance deliberately for this market rather than importing a playbook designed for somewhere else.
Frequently asked questions
Growth Finance · healthcare · Southern Europe — answered
- Does growth finance work for healthcare and life sciences in Southern Europe?
- Yes — provided it is pointed at regulated-sale cycle length, not intent and adapted to the fact that in Southern Europe, Southern European buyers reward relationship depth over transactional outreach. The healthcare teams that install this get past procurement instead of dying in it.
- How often should I run this checklist?
- Quarterly, plus any time you change ownership, tooling, or budget for growth finance.
- What is the single most important item?
- A named owner. Every other item is meaningless without one.
- What if I fail more than three items?
- Pause the spend, fix them in order, and restart at low volume rather than push through.
- Does this checklist apply at enterprise scale?
- Yes — the items are the same. Governance and escalation matter more at scale.
- What is the Southern Europe-specific pitfall when running growth finance for healthcare?
- Importing a playbook that was built for another market. In Southern Europe, Southern European buyers reward relationship depth over transactional outreach — the install has to reflect that.
Growth Broker editorial
Filed under growth finance · healthcare · southern europe